Indication
Bladder Carcinoma in Situ
2 clinical trials
4 products
Product
ONCOFID P-BClinical trial
A Phase III, Single-arm Study to Evaluate the Efficacy and Safety of ONCOFID-P-B (Paclitaxel-hyaluronic Acid Conjugate) Administered Intravesically to Patients With BCG-unresponsive Carcinoma in Situ of the Bladder With or Without Ta-T1 Papillary Disease (Orion-BC)Status: Recruiting, Estimated PCD: 2025-11-01
Product
UGN-301Clinical trial
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBCStatus: Recruiting, Estimated PCD: 2025-12-01
Product
UGN-201Product
Gemcitabine